Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Jul 17, 2021 8:24am
132 Views
Post# 33564894

RE:RE:RE:RE:RE:RE:Contrarian opinion!!!

RE:RE:RE:RE:RE:RE:Contrarian opinion!!!

I wouldn't waste any time worrying about the 4 "analysts" covering them. They can't do anything to build the investor base and stock price.  There is no "amplification" there, only a dampening effect. They don't care about the company, have highly inaccurate reports and have no following at their small firms.  Most have had targets over the last year below the share price and really are more negative and skeptical, which is why they don't spend the time to figure out the science behind SORT1+, the huge value-driver stareing them in their Cheeto stuffed faces.

It's all up to the science developing as we hope and in the company's control at this point.  If the small points of positivity we see continue to build into a clear and supportable case within the next few months, just a few mentions from some of the new shareholders to their pals is all it would take.  I'm actually surprised some of the sights like "whale watch" haven't picked up on the fact that guys like Soleus have a good record of identifying cancer oriented stocks and that THTX is their #2 holding. We're beyond needing to worry about what those analysts report since none are specialists in oncology who get it. 


scarlet1967 wrote:

During the chat with Paul Ed mentioned he will be happy to help the company with future financing, well nothing wrong with that he needs to make a living I guess that’s his priority rather than doing what he is supposed to do which would be making sure his clients get ROI. Yesterday he asked three questions two were related to partnership, I guess he wasn’t overly happy if company would raise cash elsewhere. His intentions and main concerns to earn a fee by being part of a future offering is so obvious, not a single question re oncology or sales. As for Leeds analyst hopefully he will eventually include the oncology in his analysis when and if the trial is approved so his clients don’t miss out on taking positions.

Unbelievable…

 

Wino115 wrote:

 

I think Ed can move them wherever he wants.  Some one needs to tell him no one listens to him anyway.  If we didn't hear his Cheeto munching, he'd be as inconspicuous as they come.  

Canaccord's numbers were the worst. Maybe the reason we have not yet seen a report from Ed is he is trying to figure out how to make the adjustments as inconspicuously as possible.


 





<< Previous
Bullboard Posts
Next >>